Treatment of bacterial meningitis: An update

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 15, 2012, Pages 2189-2206

  Shin, Seon Hee ^a   Kim, Kwang Sik ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacterial meningitis; Bloodbrain barrier; Central nervous system; Dexamethasone; Escherichia coli; Group B Streptococcus; Haemophilus influenzae type b; Listeria monocytogenes; Neisseria meningitidis; Neurologic sequelae

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CYTOKINE; DAPTOMYCIN; DEXAMETHASONE; GENTAMICIN; GLYCEROL; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PENICILLIN G; RIFAMPICIN; ROSCOVITINE; TELAVANCIN; TOLL LIKE RECEPTOR; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; APOPTOSIS; BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CHEMOPROPHYLAXIS; GEOGRAPHIC DISTRIBUTION; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; LABORATORY TEST; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEUTROPHIL; PATHOGENESIS; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MENINGITIS, BACTERIAL;

EID: 84866521963     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.724399     Document Type: Review

References (127)

1. World Health Organization. World health report: changing history. WHO; Geneva: 2004
2. van de Beek D, de Gans J, Tunkel AR, et al. Community-acquired bacterial meningitis in adults. N Engl J Med 2006;354:44-53 (Pubitemid 43048950)
3. Scarborough M, Thwaites GE. The diagnosis and management of acute bacterial meningitis in resource-poor settings. Lancet Neurol 2008;7:637-8
4. Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:317-28
5. Kim KS. Acute bacterial meningitis in infants and children. Lancet Infect Dis 2010;10:32-42
6. Kim KS. Pathogenesis of bacterial meningitis: from bacteremia to neuronal injury. Nature Rev Neurosci 2003;4:376-85 (Pubitemid 37280176)
7. Kim KS. Mechanisms of microbial traversal of the blood-brain barrier. Nat Rev Microbiol 2008;6:625-34
8. Koedel U, Klein M, Pfister HW. New understandings on the pathophysiology of bacterial meningitis. Curr Opin Infect Dis 2010;23:217-23
9. Blanchard-Rohner G, Pollard AJ. Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy. Expert Rev Vacc 2011;10:673-84
10. Ojo LR, O'Loughlin RE, Cohen AL, et al. Global use of Haemophilus influenza type b conjugate vaccine. Vaccine 2010;28:7117-22
11. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011;364:2016-25
12. World Health Organization. Disease Surveillance Centre Ouagadougou, Regional Meningitis Surveillance. Available from: http://www.who.int/csr/ disease/meningococcal/epidemiological/en/index.html
13. World Health Orginazation. WHO-Global Alert and Response. Available from: http://www.who.int/csr/don/2012-03-23/en/index.html
14. Vyse A, Wolter JM, Chen J, et al. Meningococcal disease in Asia: an under-recognised public health burden. Epidemiol Infect 2011;139:967-85
15. Lennon D, Jackson C, Wong S, et al. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis 2009;49:597-605
16. Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011;11:969-85
17. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012;307:573-82
18. Vesikari T, Esposito S, Prymula R, et al. Use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in a clinical trial in 3630 infants. Arch Dis Child 2011;96:11-16
19. Collard JM, Maman Z, Yacouba H, et al. Increase in Neisseria meningitidis serogroup W135, Niger, 2010. Emerg Infect Dis 2010;16:1496-8
20. Von Gottberg A, du Plessis M, Cohen C, et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 2008;46:377-86 (Pubitemid 351263521)
21. Jacobsson S, Molling P, Thulin Hedberg S, et al. Invasive meningococcal disease in Sweden. The 11th European Meningococcal Group Meeting Congress 2011. Ljubljana, Slovenia; 2010. p. 45-6.Abstract Available from http://emgm.eu/ meetings/emgm2011/abstract.pdf
22. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009;4:CD004977
23. McIntosh ED, Reinert RR. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev Vaccines 2011;10:109-29
24. World Health Organization. WHO position paper on Hib conjugate vaccines. Wkly Epidemiol Rec 2006;47:445-52
25. Swingler GH, Fransman D, Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type b infections. Cochrane Database Syst Rev 2003;4:CD001729. Update in: Cochrane Database Syst Rev 2007;2:CD001729
26. Ribeiro GS, Reis JN, Cordeiro SM, et al. Prevention of Haemophilus influenzae type B (Hib) meningitis and emergence of serotype replacement with type A strains after introduction of Hib immunization in Brazil. J Infect Dis 2003;187:109-16 (Pubitemid 36034478)
27. Ladhani S, Slack MP, Heys M, et al. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 2008;93:665-9
28. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004;351:1849-59
29. Chaudhuri A, Martin PM, Kennedy PGE, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. Eur J Neurol 2008;15:649-59 (Pubitemid 351814425)
30. Dubos F, Korczowski B, Aygun DA, et al. Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children. Arch Pediatr Adolesc Med 2008;162:1157-63
31. Alkholi UM, Abd Al-monem N, Abd El-Azim AA, et al. Serum procalcitonin in viral and bacterial meningitis. J Glob Infect Dis 2011;3:14-18
32. Determann RM, Weisfelt M, de Gans J, et al. Soluble triggering receptor expressed on myeloid cells 1: a biomarker for bacterial meningitis. Part III of a three-part series. Intensive Care Med 2006;32:1243-7 (Pubitemid 44232421)
33. Nigrovic LE, Kuppermann N, McAdm AJ, et al. Cerebrospinal latex agglutination fails to contribute to the microbiologic diagnosis of pretreated children with meningitis. Pediatr Infect Dis J 2004;23:786-8 (Pubitemid 39063301)
34. American Academy of Pediatrics. In: Pickering LK, editor. Red book: 2012 report of the committee on infectious diseases. 29th edition. American Academy of Pediatrics; Elk grove village, IL: 2012. p. 345-52; p. 500-9
35. Koster-Rasmussen R, Korshin A, Meyer CN. Antibiotic treatment delay and outcome in acute bacterial meningitis. J Infect 2008;57:449-54
36. Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit Care Med 2006;34:2758-65 (Pubitemid 44610940)
37. Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998;129:862-9 (Pubitemid 28549813)
38. National Institute for Health and Clinical Excellence. Feverish illness in children;Assessment and initial management in children younger than 5 years. NICE Clinical Guideline. Available from: http://www.nice.org.uk/nicemedia/live/ 11010/30523/30523.pdf
39. Sinner SW, Tunkel AR. Antimicrobial agents in the treatment of bacterial meningitis. Infect Dis Clin N Am 2004;18:581-602 (Pubitemid 39078730)
40. Weisfelt M, de Gans J, van de Beek D. Bacterial meningitis: a review of effective pharmacotherapy. Expert Opin Pharmacother 2007;8:1493-504 (Pubitemid 47082699)
41. Nau R, Sorgel F, Eiffert H. Penetration of drugs through the Blood-Cerebrospinal Fluid/Blood-brain barrier to treatment of central nervous system infections. Clin Microb Rev 2010;23:858-83
42. Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin N Am 2009;23:791-815
43. Andersson DI. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 2006;9:461-5 (Pubitemid 44397630)
44. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-24 (Pubitemid 32064785)
45. CDC. Centers for Disease Control and Prevention. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae-United States, 2006-2007. MMWR 2008;57:1353-5
46. Viladrich PF, Cabellos C, Pallares R, et al. High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad spectrum cephalosporins. Antimicrob Agents Chemother 1996;40:218-20 (Pubitemid 26019700)
47. Suntur BM, Yurtseven T, Sipahi OR, et al. Rifampicin + ceftriaxone versus vancomycin + ceftriaxone in the treatment of penicillin- and cephalosporin-resistant pneumococcal meningitis in an experimental rabbit model. Int J Antimicrob Agents 2005;26:258-60 (Pubitemid 41219614)
48. Faella F, Pagliano P, Fusco U, et al. Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains. Clin Microbiol Infect 2006;12:391-4 (Pubitemid 43337531)
49. Latorre C, Gene A, Juncosa T, et al. Neisseria meningitidis: evolution of penicillin resistance and phenotype in a children's hospital in Barcelona. Spain. Acta Paediatr 2000;89:661-5 (Pubitemid 30624908)
50. Luaces CC, Garcia Garcia JJ, Roca MJ, et al. Clinical data in children with meningococcal meningitis in a Spanish hospital. Acta Paediatr 1997;86:26-9 (Pubitemid 27047149)
51. Latorre C, Pineda V, Juncosa T, et al. Haemophilus influenzae meningitis in Catalonia, Spain: epidemiology and bacteriologic characteristics. Clin Microbiol Infect 2000;6:279-82 (Pubitemid 36267437)
52. Hasegawa K, Kobayashi R, Takada E, et al. High prevalence of type b betalactamase- non-producing ampicillin-resistant Haemophilus influenzae in meningitis: the situation in Japan where Hib vaccine has not been introduced. J Antimicrob Chemother 2006;57:1077-82 (Pubitemid 44644408)
53. Hof H, Nichterlein T, Kretschmar M. Management of Listeriosis. Clin Microbiol Rev 1997;10:345-57 (Pubitemid 27196675)
54. Sipahi OR, Turhan T, Pullukcu H, et al. Moxifloxacin versus ampicillin+ gentamicin in the therapy of experimental Listeria monocytogenes meningitis. J Antimicrobiol Chemother 2008;61:670-3 (Pubitemid 351321145)
55. Mitja O, Pigrau C, Ruiz I, et al. Predictors of mortality and impact of aminoglycosides on outcome in listeriosis in a retrospective cohort study. J Antimicrob Chemother 2009;64:416-23
56. Amaya-Villar R, Garcia-Cabrera E, Sulleiro-Igual E, et al. Three-year multicenter surveillance of community-acquired Listeria monocytogenes meningitis in adults. BMC Infect Dis 2010;10:324
57. Grant MH, Ravreby H, Lorber B. Cure of Listeria monocytogenes meningitis after early transition to oral therapy. Antimicrob Agents Chemother 2010;54:2276-7
58. Callapina M, Kretschmar M, Dietz A, et al. Systemic and intracerebral infections of mice with Listeria monocytogenes successfully treated with linezolid. J Chemother 2001;13:265-9 (Pubitemid 32575138)
59. Tsai YH, Bies M, Leitner F, et al. Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats. Antimicrob Agents Chemother 1990;34:733-8 (Pubitemid 20142389)
60. Kim KS, Bayer AS. Efficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci. Antimicrob Agents Chemother 1985;28:51-4 (Pubitemid 15029691)
61. Brassi GG, Grassi C. Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother 1993;32:B87-94
62. Cottagnoud P, Acosta F, Cottagnoud M, et al. Cefepime is efficacious against penicillin- and quinolone-resistant pneumococci in experimental meningitis. J Antimicrob Chemother 2002;49:327-30 (Pubitemid 34162624)
63. Saez-Llorens X, O'Ryan M. Cefepime in the empiric treatment of meningitis in children. Pediatr Infect Dis J 2001;20:356-61 (Pubitemid 32240288)
64. Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008;68:803-38 (Pubitemid 351559562)
65. Schmutzhard E, Williams KJ, Vukmirovits G, et al. A randomized comparison of meropenem with cefotaxime and ceftriaxone for the treatment of bacterial meningitis in adults: meropenem meningitis study group. J Antimicrob Chemother 1995;36(Suppl A):85-97
66. Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 1995;39:1140-6
67. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J Antimicrob Chemother 1996;38:523-37 (Pubitemid 26381670)
68. Odio CM, Puig JR, Feris JM, et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J 1999;18:581-90 (Pubitemid 29350323)
69. Gerber CM, Cottagnoud M, Neftel KA, et al. Meropenem alone and in combination with vancomicin in experimental meningitis caused by a penicillin-resistant pneumoccocal strain. Eur J Clin Microbiol Infect Dis 1999;18:886-70
70. Friedland IR, Paris M, Ehrett S, et al. Evaluation of antimicrobial regimens for treatment of experimental penicillin and cephalosporin resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993;37:1630-6 (Pubitemid 23226374)
71. Force E, Taberner F, Cabellos C, et al. Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis. Eur J Clin Microbiol Infect Dis 2008;27:685-90
72. Fukasawa M, Sumita Y, Harabe ET, et al. Stability of meropenem and effect of 1beta-methil substitution on its stability in the presence of renal dehydropeptidase I. J Antimicrobial Chemother 1992;36:1577-9
73. Kim KS. Current concepts on the pathogenesis of E. coli meningitis; implications for prevention and therapy. Curr Opin Infect Dis 2012;25:273-8
74. Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004;48:3928-33 (Pubitemid 39304623)
75. Kullar R, Chin JN, Edwards DJ, et al. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother 2011;55:3505-9
76. Grandgirard D, Schurch C, Cottagnoud P, et al. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2007;51:2173-8 (Pubitemid 46903110)
77. Grandgirard D, Oberson K, Buhlmann A, et al. Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2010;54:1323-6
78. Denis G, Melchior B, Philipp A, et al. Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampicin in infant rat pneumococcal meningitis. Antimicrob Agents Chemother 2012;56(8):4289-95
79. Corti G, Cinelli R, Paradisi F. Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic. Int J Antimicrob Agents 2000;16:527-30
80. Cottagnoud P, Gerber CM, Acosta F, et al. Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 2000;46:981-5 (Pubitemid 32000609)
81. Bressler AM, Zimmer SM, Gilmore JL, et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004;4:528-31 (Pubitemid 39077924)
82. Marshall SH, Donskey CJ, Hutton-Thomas R, et al. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002;46:3334-6
83. Attwood RJ, LaPlante KL. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 2007;64:2335-48 (Pubitemid 350174705)
84. Stucki A, Gerber P, Acosta F, et al. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 2006;50:770-3 (Pubitemid 43190998)
85. Ostergaard C, Sorensen TK, Knudsen JD, et al. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob Agents Chemother 1998;42:1706-12 (Pubitemid 28311566)
86. Schmidt H, Dalhoff A, Stuertz K, et al. Moxifloxacin in the therapy of experimental pneumococcal meningitis. Antimicrob Agents Chemother 1998;42:1397-401 (Pubitemid 28257639)
87. Kanellakopoulou K, Pagoulatou A, Stroumpoulis K, et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid in humans: implication for a bactericidal effect. J Antimicrob Chemother 2008;61:1328-31 (Pubitemid 351753602)
88. Alffenaar JW, van Altena R, Bokkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009;49:1080-2
89. Luo HR, Loison F. Constitutive neutrophil apoptosis: mechanisms and regulation. Am J Hematol 2008;83:288-95 (Pubitemid 351458006)
90. Galons H, Oumata N, Meijer L. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin Ther Pat 2010;20:377-404
91. Koedel U, Frankenberg T, Kirschnek S, et al. Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal meningitis. PloS Pathog 2009;5:e1000461
92. Glimaker M, Olcen P, Andersson B. Interferon-gamma in cerebrospinal fluid from patients with viral and bacterial meningitis. Scand J Infect Dis 1994;26:141-7
93. Paris MM, Hickey SM, Trujillo M, et al. The effect of interleukin-10 on meningeal inflammation in experimental bacterial meningitis. J Infect Dis 1997;176:1239-46 (Pubitemid 27460989)
94. Chauhan VS, Kluttz JM, Bost KL, et al. Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis. J Immunol 2011;186:7255-63
95. Ebert S, Phillips DJ, Jenzewski P, et al. Activin A concentrations in human cerebrospinal fluid are age-dependent and elevated in meningitis. J Neurol Sci 2006;250:50-7 (Pubitemid 44665929)
96. Wilms H, Schwark T, Bradenburg LO, et al. Regulation of activin A synthesis in microglial cells: pathophysiological implications for bacterial meningitis. J Neurosci Res 2010;88:16-23
97. Oliver R, Staples KJ, Heckels J, et al. Coadministration of the cyanobacterial lipopolysaccharide antagonist CyP with antibiotic inhibits cytokine production by an in vitro meningitis model infected with Neisseria meningitidis. J Antimicrob Chemother 2012;67:1145-54
98. Koedel U. Toll-like receptors in bacterial meningitis. Curr Top Microbiol Immunol 2009;336:15-40
99. Lewin GR, Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci 1996;19:289-317 (Pubitemid 26080831)
100. Demel C, Hoegen T, Giese A, et al. Reduced spiral ganglion neuronal loss by adjunctive neurotrophin-3 in experimental pneumococcal meningitis. J Neuroinflammation 2011;8:7
101. Li L, Shui QX, Li X. Neuroprotective effects of brain-derived neurotrophic factor (BDNF) on hearing in experimental pneumococcal meningitis. J Child Neurol 2005;20:51-6 (Pubitemid 40394268)
102. Koedel U, Winkler F, Angele B, et al. Role of Caspase-1 in experimental pneumococcal meningitis: evidence from pharmacologic Caspase inhibition and Caspase-1-deficient mice. Ann Neurol 2002;51:319-29 (Pubitemid 34206288)
103. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. Results of two double blind, placebo-controlled trials. N Engl J Med 1988;319:964-71
104. Odio CM, Faingezicht I, Paris M, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991;324:1525-31
105. Schaad UB, Lips U, Gnehm HE, et al. Dexamethasone therapy for bacterial meningitis in children. Swiss Meningitis Study Group. Lancet 1993;342:457-61 (Pubitemid 23240309)
106. Arditi M, Mason EO Jr, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 1998;102:1087-97 (Pubitemid 28511715)
107. Molyneux EM, Walsh AL, Forsyth H, et al. Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomized control trial. Lancet 2002;360:211-18 (Pubitemid 34804649)
108. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347:1549-56 (Pubitemid 35315835)
109. Mai NTH, Chau TTH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med 2007;357:2431-40 (Pubitemid 350272782)
110. van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 2010;9:254-63
111. Brouwer MC, McIntyre P, de Gans J, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Sys Rev 2010;9:CD004405
112. Leib SL, Heimgartner C, Bifrare YD, et al. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr Res 2003;54:353-7 (Pubitemid 37013197)
113. Spreer A, Gerber J, Hanssen M, et al. Dexamethasone increases hippocampal neuronal apoptosis in a rabbit model of Escherichia coli meningitis. Pediatr Res 2006;60:210-15 (Pubitemid 44297595)
114. Singhi S, Jarvinen A, Petola H. Increase in serum osmolality is possible mechanism for the beneficial effects of glycerol in childhood bacterial meningitis. Pediatr Infect Dis J 2008;27:892-6
115. Peltola H, Roine I, Fernandez J, et al. Hearing Impairment in Childhood Bacterial Meningitis is Little Relieved by Dexamethasone or Glycerol. Pediatrics 2010;125:e1-8
116. Ajdukiewicz KM, Cartwright KE, Scarborough M, et al. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis 2011;11:293-300
117. Unkmeir A, Latsch K, Detrich G, et al. Fibronectin mediates Opc-dependent internalization of Neisseria meningitidis in human brain microvascular endothelial cells. Mol Microbiol 2002;46:933-46 (Pubitemid 35370583)
118. Nassif X, Beretti JL, Lowy J, et al. Roles of pilin and PilC in adhesion of Neisseria meningitidis to human epithelial and endothelial cells. Proc Natl Acad Sci USA 1994;91:3769-73 (Pubitemid 24139513)
119. Coureuil M, Lecuyer H, Scott MG, et al. Meningococcus Hijacks a beta2- adrenoceptor/beta-Arrestin pathway to cross brain microvasculature endothelium. Cell 2010;143:1149-60
120. Ring A, Weiser JN, Tuomanen EI. Pneumococcal trafficking across the blood-brain barrier. Molecular analysis of a novel bi-directional pathway. J Clin Invest 1998;102:347-60 (Pubitemid 28335194)
121. Greiffenberg L, Goebel W, Kim KS, et al. Interaction of Listeria monocytogenes with human brain microvascular endothelial cells: inlB-dependent invasion, long-term intracellular growth and spread from macrophages to endothelial cells. Infect Immun 1998;66:5260-7 (Pubitemid 29044618)
122. Takeuchi O, Hoshino K, Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000;165:5392-6
123. Kieseier BC, Paul R, Koedel U, et al. Differential expression of matrix metalloproteinases in bacterial meningitis. Brain 1999;122:1579-87 (Pubitemid 29374132)
124. CDC. Comparison of meningococcal disease surveillance systems-United States. 2005-2008. MMWR 2012;61:306-8
125. Safadi MA, Cintra O. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res 2010;32:263-71
126. European Centre for Disease Prevention and Control (ECDC). Surveillance report on invasive bacterial diseases in Europe for 2008 - 2009. Available from: http://ecdc.europa.eu/en/activities/diseaseprogrammes/vpd/Pages/index
127. Chiu C, Dey A, Wang H, et al. Vaccine preventable diseases in Australia, 2005 - 2007. Commun Dis Intell 2010;34:S81-3